LATE-BREAKING ABSTRACT: Benralizumab for mild to moderate, persistent asthma: The BISE phase III study

Gary Ferguson (Farmington Hills, United States of America), Gary Ferguson, J. Mark FitzGerald, Eugene Bleecker, Michel Laviolette, David Bernstein, Craig LaForce, Lyndon Mansfield, Peter Barker, Yanping Wu, Maria Jison, Mitchell Goldman

Source: International Congress 2016 – Asthma: from basic mechanisms to novel therapeutic perspectives
Session: Asthma: from basic mechanisms to novel therapeutic perspectives
Session type: Oral Presentation
Number: 1791
Disease area: Airway diseases

Congress or journal article abstractSlide presentationE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Gary Ferguson (Farmington Hills, United States of America), Gary Ferguson, J. Mark FitzGerald, Eugene Bleecker, Michel Laviolette, David Bernstein, Craig LaForce, Lyndon Mansfield, Peter Barker, Yanping Wu, Maria Jison, Mitchell Goldman. LATE-BREAKING ABSTRACT: Benralizumab for mild to moderate, persistent asthma: The BISE phase III study. Eur Respir J 2016; 48: Suppl. 60, 1791

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
LATE-BREAKING ABSTRACT: Benralizumab reduces exacerbations in severe, uncontrolled asthma: Results of the phase III CALIMA trial
Source: International Congress 2016 – Late-breaking topics in airways disease
Year: 2016



LATE-BREAKING ABSTRACT: Benralizumab provides significant improvements for patients with severe, uncontrolled asthma: SIROCCO Phase III results
Source: International Congress 2016 – Novel strategies on COPD and asthma management
Year: 2016


LATE-BREAKING ABSTRACT: Vocal cord dysfunction (VCD) in mild and severe asthma
Source: International Congress 2016 – Features and impact of comorbidities in COPD
Year: 2016


LATE-BREAKING ABSTRACT: Disease control rate (DRC) of bronchial asthma during pregnancy
Source: Annual Congress 2013 –Diagnosis and management of respiratory diseases
Year: 2013


LATE-BREAKING ABSTRACT: The analysis of the severe asthma prevalence rate in China
Source: International Congress 2016 – Prevalence of obstructive airway diseases, methods of diagnosis, and lung function testing
Year: 2016


LATE-BREAKING ABSTRACT: Anti-interleukin-5 in severe asthma: Blood eosinophilia predicts lung function improvement
Source: Annual Congress 2013 –Origins and diagnosis of asthma
Year: 2013

Comparison of clinical features of severe persistent asthma and refractory asthma
Source: Annual Congress 2013 –Phenotyping asthma: clinical severity, comorbid conditions response to treatment?
Year: 2013


LATE-BREAKING ABSTRACT: Multinational, database cohort study to assess severe exacerbation rate in asthma
Source: International Congress 2015 – Asthma and COPD: overlap and exacerbations
Year: 2015


Prevalence of refractory asthma in population with severe asthma
Source: International Congress 2016 – Phenotyping and monitoring airway diseases
Year: 2016


Characterisation of asthma patients with persistent airflow obstruction
Source: International Congress 2016 – Clinical studies in asthma and immunology
Year: 2016


Reproducibility and stability of severe asthma research program (SARP) clinical cluster phenotypes in SARP3
Source: International Congress 2016 – Phenotyping asthma
Year: 2016

Tiotropium for uncontrolled asthma (a meta-analysis)
Source: Annual Congress 2013 –Treatment of asthma
Year: 2013



QAW039 (fevipiprant) improves lung function and control of asthma symptoms in patients with more severe air flow limitation: A proof-of-concept study
Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD
Year: 2015


An extensive function evaluation in severe asthma with airflow limitation
Source: International Congress 2014 – Asthma: still a heterogeneous condition!
Year: 2014


LATE-BREAKING ABSTRACT: A phase 2 study of benralizumab on exacerbations, lung function, and asthma control in adults with uncontrolled eosinophilic asthma
Source: International Congress 2014 – The future has started: emerging potentials for personalised asthma treatment
Year: 2014


Markers of eosinophilic airway inflammation in patients with severe and mild to moderate asthma
Source: International Congress 2016 – Airway biomarkers
Year: 2016

Childhood obesity in relation to poor asthma control and exacerbations
Source: International Congress 2016 – Paediatric asthma: lessons learned from studies with large sample sizes and multi-centre drug studies
Year: 2016


Chronic rhinosinusitis with and without nasal polyps and rhinitis in adult asthma. Frequency distribution and relationship with asthma control and severity (the IRIS-ASMA study)
Source: Annual Congress 2013 –Comorbidities and respiratory disease and late-breaking abstracts
Year: 2013


LATE-BREAKING ABSTRACT: Reslizumab in patients with late-onset asthma with elevated blood eosinophils
Source: International Congress 2015 – Hot topics on airway diseases: new horizons in treatment
Year: 2015

The asthma-COPD, overlap syndrome, our clinical experience
Source: International Congress 2014 – Asthma or COPD: comorbid condition or a poorly understood single disease?
Year: 2014